Abstract:Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy determinants in cancer patients. These features are typical of early-memory T cells, which can be enriched with specific manufacturing procedures, providing signal one and signal two in the proper steric conformation and in the presence of homeostatic cytokines. In this project, we exploited our expertise with paramagnetic beads and IL-7/IL-15 to develop an optimized protocol for CAR T cell production based on reagents, including a polymeric nanomatrix, which are compatible with automated manufacturing via the CliniMACS Prodigy. We found that both procedures generate similar CAR T cell products, highly enriched of stem cell memory T cells (TSCM) and equally effective in counteracting tumor growth in xenograft mouse models. Most importantly, the optimized protocol was able to expand CAR TSCM from B-cell acute lymphoblastic leukemia (B-ALL) patients, which in origin were highly enriched of late-memory and exhausted T cells. Notably, CAR T cells derived from B-ALL patients proved to be as efficient as healthy donor-derived CAR T cells in mediating profound and prolonged anti-tumor responses in xenograft mouse models. On the contrary, the protocol failed to expand fully functional CAR TSCM from patients with pancreatic ductal adenocarcinoma, suggesting that patient-specific factors may profoundly affect intrinsic T cell quality. Finally, by retrospective analysis of in vivo data, we observed that the proportion of TSCM in the final CAR T cell product positively correlated with in vivo expansion, which in turn proved to be crucial for achieving long-term remissions. Collectively, our data indicate that next-generation manufacturing protocols can overcome initial T cell defects, resulting in TSCM-enriched CAR T cell products qualitatively equivalent to the ones generated from healthy donors. However, this positive effect may be decreased in specific conditions, for which the development of further improved protocols and novel strategies might be highly beneficial.

Optimizing the manufacturing and antitumour response of CAR T therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Tuning CAR T-cell therapies for efficacy and reduced toxicity

Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Recent advances in CAR-T cell engineering

Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

Navigating CAR-T cells through the solid-tumour microenvironment

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients

Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies